Registration Document

Overview

The report presents ABIVAX as a clinical-stage biotech focused on antiviral and immunostimulant research, with ABX 464 advancing through phase IIa studies. It reports no revenue for 2016 while R&D expenses reached EUR15,459K and the net loss was EUR14,308K. The CSR section records 24 employees at year-end, estimated water consumption of 291 m3, and independent review of the social, environmental and societal information.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2016
Period: Ends 31 December 2016
Publication date: 11 May 2017
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Materiality

Assessment
Basis

Assurance

Provider
Level
Standard
Scope
Statement included
Metrics assured

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services